retatrutide investigational drug weight loss UK: New Triple-Agonist Injection Explained Retatrutide - “Triple G” |

doi:10.1136/bmj-2023-078225 Baxter SM, Lund LC, Andersen JH, Brix TH, Hegeds L, Hsieh MH, Su CT, Cheng MC, Chang ZC, Lai EC, Hussain S, Chu C, Gomes T, Antoniou T, Eskander A, Bouck Z, Tadrous M, Bea S, Choi EY, Shin JY, Modig K, Talbck M, Ljung R, Gulseth HL, Karlstad , Hicks B, Pottegrd A

Sharretts J, Galescu O, Gomatam S

Clear, measurable ROI and simple reporting

A diferencia de los mono y dual agonistas, semaglutida y tirzepatida, la retatrutida introduce el triple agonismo al dirigirse simultneamente a los receptores del pptido similar al glucagn-1 ( GLP-1 ), del polipptido insulinotrpico dependiente de glucosa ( GIP ) y, de manera crucial, al receptor de glucagn (GCGR)

Chat is your fastest path to a real person